Recombinant Human PDCD1 Protein, Fc tagged, PE Labeled

• Cat.No.: PDCD1-255H
• Product Overview: Human PD-1 protein (NP_005009.2) (Leu25-Gln167) with C-terminus Fc tag is expressed in HEK293 cells and conjugated to PE

Specification

• Species: Human
• Source: HEK293
• Tag: Fc
• Protein Length: PE
• Conjugation/Label: 25-167 aa aa
• Description: CD279, also known as Programmed Cell Death Protein 1 (PD-1), is a crucial immune checkpoint receptor that regulates T cell activation and prevents autoimmunity. This transmembrane protein plays a pivotal role in maintaining immune homeostasis by delivering inhibitory signals that dampen excessive immune responses. PD-1 is a type I transmembrane glycoprotein belonging to the immunoglobulin superfamily. It contains an extracellular immunoglobulin variable (IgV)-like domain, a transmembrane region, and an intracellular tail with two tyrosine-based signaling motifs: an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM). When engaged, these motifs recruit phosphatases that inhibit T-cell receptor signaling, effectively suppressing T-cell activation, proliferation, and cytokine production. PD-1 interacts with two primary ligands: PD-L1 (B7-H1/CD274) and PD-L2 (B7-DC/CD273). PD-L1 is widely expressed on various cell types, including tumor cells, antigen-presenting cells, and non-hematopoietic tissues, while PD-L2 expression is more restricted to antigen-presenting cells. These ligand-receptor interactions serve as critical brakes on immune responses. In cancer, tumor cells exploit the PD-1/PD-L1 pathway to evade immune surveillance. By upregulating PD-L1 expression, tumors effectively "turn off" infiltrating T-cells, preventing effective anti-tumor immunity. This mechanism contributes to tumor progression and immune escape across multiple cancer types. The discovery of PD-1's role in cancer has revolutionized oncology through immune checkpoint inhibitors. Monoclonal antibodies targeting PD-1 (pembrolizumab, nivolumab) or PD-L1 (atezolizumab, durvalumab) block this inhibitory pathway, reinvigorating anti-tumor T-cell responses. These therapies have demonstrated remarkable success in treating melanoma, non-small cell lung cancer, renal cell carcinoma, and numerous other malignancies, fundamentally transforming cancer treatment paradigms and offering durable responses in previously untreatable cancers.
• Form: Liquid, 1×PBS buffer, pH7.4, 0.09% NaN3 with a carrier protein
• Molecular Mass: The protein has a predicted molecular weight of 44 kDa. Under DTT-reducing conditions, it migrates at approximately 60 kDa on SDS-PAGE prior to conjugation.
• Applications: Flow Cytometry
• Storage: Briefly centrifuge the vial upon receipt. An unopened vial may be stored at 2–8 centigrade for up to six months.
• Concentration: 25 μg size is bottled at 0.1 mg/mL concentration. 100 μg size is bottled at lot specific concentration.

Gene Information

• Gene Name: PDCD1 programmed cell death 1 [ Homo sapiens (human) ]
• Official Symbol: PDCD1
• Synonyms: PDCD1; programmed cell death 1; programmed cell death protein 1; CD279; PD1; protein PD-1; PD-1; SLEB2; hPD-1; hPD-l
• Gene ID: 5133
• mRNA Refseq: NM_005018
• Protein Refseq: NP_005009
• MIM: 600244
• UniProt ID: Q15116